In our exploration of chronic urticaria, we discovered how a combination treatment involving mizolastine, proteoglycan, and vitamin D can be effective. The study included a randomized design with two groups: one receiving the full treatment and the other receiving the same regimen minus proteoglycan. Over four weeks, we observed that those in the treatment group experienced a significant improvement in their symptoms. Specifically, 44 out of 56 patients showed a decline in symptoms by over 60% compared to just 24 out of 44 in the control group.
Alongside these findings, we noted a lower relapse rate for the treatment group after two months, dropping to 17.9% compared to 38.6% for the control group. Importantly, the levels of a key immune marker, IFN-γ, were higher in the group that received proteoglycan, suggesting it plays a role in enhancing the effectiveness of the treatment. While vitamin D was part of the overall protocol, separating its specific contributions is challenging due to the combined treatment nature.
Overall, our findings suggest that while vitamin D was included in the regimen, the stronger efficacy came from the combination with mizolastine and proteoglycan. This highlights the need for further studies focusing on the isolated impacts of vitamin D on hives to really understand its role more precisely.